New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
09:21 EDTREGNRegeneron trading halted, pending news
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:31 EDTREGNRegeneron's EYLEA Injection granted designation for treatment of retinopathy
Subscribe for More Information
September 8, 2014
07:15 EDTREGNIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
September 4, 2014
05:37 EDTREGNRegeneron submits application for Eylea injection in Japan for macular edema
Subscribe for More Information
September 2, 2014
13:58 EDTREGNRegeneron expected to receive priority review at Piper Jaffray
Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
13:48 EDTREGNRegeneron price target raised to $390 from $380 at Brean Capital
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $436 from $389 at Leerink
Leerink raised its price target for Regeneron shares to $436 after its survey of 100 physicians indicated potential blockbuster status for the company's PCSK9-inhibitor Alirocumab. The firm reiterates an Outperform rating on the stock.
07:21 EDTREGNRegeneron data positive, says RBC Capital
Subscribe for More Information
07:14 EDTREGNRegeneron price target raised to $400 from $340 at Credit Suisse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use